Semax

Also known as: MEHFPGP, Semax 0.1%

Cognitive Enhancement

Preclinical

Semax is a synthetic heptapeptide derived from ACTH that has been approved in Russia as a neuroprotective and nootropic medication. Unlike ACTH, it has no hormonal (steroidogenic) activity. It demonstrates neuroprotective, nootropic, and neurotrophic effects through multiple CNS pathways.

Regulatory & Approval Status

Not FDA Approved

Semax is not FDA-approved; while it was recommended for the 503A bulks list by an advisory committee in July 2026, this is a non-binding recommendation and does not constitute FDA approval.

Information compiled from FDA compounding guidance and public regulatory sources. For research and educational purposes only; not medical advice.

Unlock the complete research profile

Create your free CertifiedTide account to access full compound details, mechanisms, safety data, and research tools.